Attention Deficit Hyperactivity Disorder (ADHD) Stimulants Step Therapy
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs commercial/Exchange pharmacy-benefit coverage for stimulant medications used primarily to treat attention-deficit/hyperactivity disorder. First-line agents are available without prior authorization, while second-line agents require specified prior use, clinical exception criteria, or documentation for members who are new to the plan.
Quillichew ER was removed from the policy because it is moving to nonformulary status.
Generic Mydayis was added to the step-therapy program.
The policy added criteria for members who are new to the plan.
Quantity limits were added to the policy.
Approval criteria were updated to allow lisdexamfetamine capsules for binge-eating disorder.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.